Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

By Prakhar Srivastava and Pritam Biswas (Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable ...

Image credit: Shutterstock/ Tada Images. US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...